93 related articles for article (PubMed ID: 29983871)
1. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth
Shinoda S; Kaino S; Amano S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
Oncotarget; 2018 Jun; 9(47):28434-28444. PubMed ID: 29983871
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
3. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer.
Zhao Y; Zheng Y; Zhu Y; Zhang Y; Zhu H; Liu T
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575569
[TBL] [Abstract][Full Text] [Related]
4. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
5. Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
Mitsuno M; Kitajima Y; Ohtaka K; Kai K; Hashiguchi K; Nakamura J; Hiraki M; Noshiro H; Miyazaki K
Int J Oncol; 2010 Feb; 36(2):341-9. PubMed ID: 20043067
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
[TBL] [Abstract][Full Text] [Related]
7. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
8. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
Saeki I; Yamamoto N; Yamasaki T; Takami T; Maeda M; Fujisawa K; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Uchida K; Tani K; Sakaida I
World J Gastroenterol; 2016 Oct; 22(40):8967-8977. PubMed ID: 27833388
[TBL] [Abstract][Full Text] [Related]
9. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
[TBL] [Abstract][Full Text] [Related]
10. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.
Wang B; Shen C; Li Y; Zhang T; Huang H; Ren J; Hu Z; Xu J; Xu B
Onco Targets Ther; 2019; 12():5751-5765. PubMed ID: 31410021
[No Abstract] [Full Text] [Related]
11. Iron chelation promotes 5-aminolaevulinic acid-based photodynamic therapy against oral tongue squamous cell carcinoma.
Qin J; Zhou C; Zhu M; Shi S; Zhang L; Zhao Y; Li C; Wang Y; Wang Y
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101907. PubMed ID: 32619712
[TBL] [Abstract][Full Text] [Related]
12. Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.
Legendre C; Avril S; Guillet C; Garcion E
BMC Cancer; 2016 Feb; 16():51. PubMed ID: 26832741
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
14. Anti-leukemic properties of deferasirox via apoptosis in murine leukemia cell lines.
Jeon SR; Lee JW; Jang PS; Chung NG; Cho B; Jeong DC
Blood Res; 2015 Mar; 50(1):33-9. PubMed ID: 25830128
[TBL] [Abstract][Full Text] [Related]
15. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ
Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199
[TBL] [Abstract][Full Text] [Related]
16. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
17. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
Tury S; Assayag F; Bonin F; Chateau-Joubert S; Servely JL; Vacher S; Becette V; Caly M; Rapinat A; Gentien D; de la Grange P; Schnitzler A; Lallemand F; Marangoni E; Bièche I; Callens C
J Pathol; 2018 Sep; 246(1):103-114. PubMed ID: 29876931
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral iron chelator deferasirox on human malignant lymphoma cells.
Choi JG; Kim JL; Park J; Lee S; Park SJ; Kim JS; Choi CW
Korean J Hematol; 2012 Sep; 47(3):194-201. PubMed ID: 23071474
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib.
Yamamoto N; Yamasaki T; Takami T; Uchida K; Fujisawa K; Matsumoto T; Saeki I; Terai S; Sakaida I
J Clin Biochem Nutr; 2016 May; 58(3):202-9. PubMed ID: 27257345
[TBL] [Abstract][Full Text] [Related]
20. Triptolide enhances the sensitivity of pancreatic cancer PANC-1 cells to gemcitabine by inhibiting TLR4/NF-κB signaling.
Ma JX; Sun YL; Yu Y; Zhang J; Wu HY; Yu XF
Am J Transl Res; 2019; 11(6):3750-3760. PubMed ID: 31312385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]